In recent years, with the development of next generation sequencing (NGS) and other technologies, deep sequencing and single cell sequencing technologies have flourished, and the implementation of the Global Tumor Genome Project and the completion of The Cancer Genome Atlas (TCGA) have created favorable conditions for efficient and accurate personalized sequencing of patients. Currently, detection of possible neoantigens from NGS data begins with WES of tumor and normal DNA to map tumor-specific genetic abnormalities. Immunogenomics strategies are greatly accelerated by using NGS to compare genetic changes between tumor and normal tissue.
Learn more：